PX1 Research supplies USA-manufactured CJC-1295 and Ipamorelin co-formulations engineered specifically for qualified academic, clinical, and institutional research applications. Each lot undergoes comprehensive analytical validation—including RP-HPLC purity verification, mass spectrometry sequence confirmation, and endotoxin quantification—to ensure strict experimental reproducibility in cellular and animal models.
PX1 Research supplies USA-manufactured CJC-1295 and Ipamorelin co-formulations engineered specifically for qualified academic, clinical, and institutional research applications. Each lot undergoes comprehensive analytical validation—including RP-HPLC purity verification, mass spectrometry sequence confirmation, and endotoxin quantification—to ensure strict experimental reproducibility in cellular and animal models.
To buy CJC Ipamorelin research peptide formulations for laboratory evaluation, researchers require analytical-grade compounds with verified purity, precise molecular mass, and low endotoxin levels. The combination of CJC-1295 (without DAC) and Ipamorelin represents a dual-agonist approach designed to stimulate physiological growth hormone (GH) secretion in vitro and in animal models without significant elevation of off-target hormones such as cortisol or prolactin.
When procuring these compounds for institutional studies, verified supply chains are critical. PX1 Research provides batch-specific documentation, including a full third-party Certificate of Analysis (COA) for every lot, ensuring raw material integrity and analytical consistency across all experimental protocols.
The CJC-1295 and Ipamorelin co-formulation leverages two distinct pharmacological pathways within the somatotropic axis. CJC-1295 is a synthetic 29-amino acid peptide derivative of growth hormone-releasing hormone (GHRH). It binds selectively to the GHRH receptor (GHRHR) on pituitary somatotropes, activating the adenylate cyclase-cAMP signaling cascade to stimulate growth hormone synthesis and secretion.
In contrast, Ipamorelin is a pentapeptide that acts as a selective agonist at the growth hormone secretagogue receptor (GHSR-1a), mimicking the endogenous ligand ghrelin. When researchers evaluate both compounds simultaneously, preclinical literature indicates a synergistic amplification of total growth hormone output. Rather than acting additively, the concurrent activation of GHRHR and GHSR-1a pathways leads to elevated intracellular calcium flux and enhanced exocytosis of GH storage vesicles.
This dual-action mechanism allows laboratory researchers to study physiological GH dynamics with greater receptor activation efficiency than single-agent models typically afford. Detailed structural parameters for these individual agents can be reviewed via our dedicated catalog entries for CJC-1295 No DAC and Ipamorelin.
A major area of investigation surrounding the CJC-1295/Ipamorelin combination is its capacity to promote natural, pulsatile growth hormone release rather than tonic, sustained elevations. In rodent and non-human primate models, pulsatile GH secretion closely mirrors endogenous circadian patterns, preserving normal receptor sensitivity and downstream signal transduction pathways, such as hepatic IGF-1 transcription.
Furthermore, in vitro pituitary cell assays demonstrate exceptional receptor selectivity. Unlike older growth hormone secretagogues (such as GHRP-2 or GHRP-6), Ipamorelin does not significantly trigger the release of adrenocorticotropic hormone (ACTH) or prolactin. Experimental data confirm that cortisol and prolactin levels remain at baseline concentrations during Ipamorelin administration, preventing confounding neuroendocrine variables in stress-response assays.
Preclinical studies evaluating CJC-1295 without DAC demonstrate a short plasma half-life (approximately 30 minutes), which allows investigators to control the duration of receptor stimulation precisely. This rapid clearance profile prevents continuous, non-pulsatile receptor desensitization, making the blend ideal for short-course pulsatile secretion studies in vitro.
When designing protocols to investigate the somatotropic axis, researchers must select appropriate comparative controls or single-agent alternatives. The CJC-1295 and Ipamorelin combination offers a unique balance of receptor specificity and physiological secretion patterns compared to other GHRH derivatives and secretagogues.
For instance, Tesamorelin is a stabilized 44-amino acid GHRH analogue primarily studied for its potent transactivation of GHRH receptors and downstream lipid metabolism effects. While highly effective as a single agent, it does not utilize the GHSR-1a pathway. Similarly, Sermorelin—a truncated 29-amino acid GHRH fragment—shares a similar receptor-binding domain with CJC-1295 but exhibits a significantly shorter half-life and less pronounced synergistic potentiation when administered without a ghrelin receptor agonist.
By contrast, older ghrelin mimetics like GHRP-6 provide strong GH release but suffer from significant off-target activation of hunger signals and transient elevations in systemic cortisol and prolactin. The CJC/Ipamorelin dual-peptide strategy remains the preferred standard in modern preclinical paradigms focused purely on isolated, pulsatile GH release. Researchers can explore PX1's full range of secretagogues via the all research peptides directory.
To maintain high experimental fidelity, synthetic peptides must adhere to rigid chemical specifications. CJC-1295 (modified GRF 1-29) possesses the chemical formula C152H252N44O42 and a molecular weight of 3367.2 g/mol. Ipamorelin possesses the molecular formula C38H49N9O5 and a molecular weight of 711.86 g/mol.
At PX1 Research, co-lyophilized and single-agent formulations are manufactured using solid-phase peptide synthesis (SPPS) protocols under strict quality controls. Each finished lot is guaranteed to meet a minimum purity standard of 99.0% as determined by Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC). Mass spectrometry (ESI-MS or MALDI-TOF) is conducted concurrently to verify molecular mass and confirm the absence of truncated sequences or amino acid deletions.
Research outcomes can be compromised by trace impurities, manufacturing byproducts, or bacterial endotoxins. Endotoxins (lipopolysaccharides derived from Gram-negative bacterial cell walls) can induce inflammatory responses in cell cultures and animal models, producing false-positive or irreproducible data in metabolic and endocrine assays.
PX1 Research enforces stringent endotoxin limits, testing all lots via Limulus Amebocyte Lysate (LAL) assays to ensure levels remain well below standard preclinical safety thresholds (<0.01 EU/μg). Every batch shipped from our facilities includes access to a lot-specific third-party Certificate of Analysis issued by an independent ISO 17025 accredited laboratory.
Our analytical testing protocols include:
• High-Performance Liquid Chromatography (HPLC) for purity quantification (>99.0% standard) • Electrospray Ionization Mass Spectrometry (ESI-MS) for absolute molecular weight identification • Endotoxin Quantification (LAL Assay) • Residual Solvent Analysis via Gas Chromatography (GC-MS) • Visual Appearance and Lyophilization Matrix Consistency Validation
Proper handling and reconstitution are essential to maintain the structural integrity of synthetic peptides during laboratory experimentation. Lyophilized CJC-1295 and Ipamorelin are supplied as stable, vacuum-sealed cakes or powders requiring reconstitution prior to assay introduction.
Standard laboratory protocols recommend reconstituting lyophilized peptide cakes using Bacteriostatic Water (0.9% benzyl alcohol) or sterile, endotoxin-free Phosphate-Buffered Saline (PBS, pH 7.4), depending on the specific downstream assay requirement. Reconstitution should be performed by gently running the diluent down the glass vial wall, followed by smooth swirling. Mechanical agitation, vigorous shaking, or vortexing must be avoided, as shear forces can induce peptide denaturation or aggregation.
For bulk assay setup or automated high-throughput liquid handling, laboratories can consult our wholesale peptide portal for specialized packaging and technical support documentation.
Lyophilized CJC-1295/Ipamorelin complexes exhibit high thermal stability when stored dry. For long-term preservation, unopened vials should be maintained at -20°C or -80°C in a desiccated environment to prevent moisture uptake. Under these conditions, the peptide matrix remains stable for up to 24 months without measurable degradation.
Following reconstitution, liquid solutions should be kept refrigerated at 2°C to 8°C and utilized within 28 days when formulated with bacteriostatic preservatives. Unpreserved aqueous solutions should be used immediately or aliquoted into single-use research volumes and frozen at -80°C to avoid repeated freeze-thaw cycles.
All products supplied by PX1 Research are shipped directly from primary fulfillment centers located in California and Arizona. Same-day shipping is provided for laboratory orders placed Monday through Friday prior to cutoff times, ensuring rapid cold-chain delivery to preserve compound integrity.
PX1 Research is dedicated to maintaining the highest standards in peptide manufacturing. All synthesis, purification, and packaging operations are performed in USA-based, GMP-compliant facilities subject to stringent quality management protocols.
By utilizing ISO 17025 accredited testing laboratories for independent lot verification, we offer institutional researchers full transparency and batch traceability. When you choose to order from PX1 Research, you ensure that your research program is backed by verified chemical purity, rapid domestic distribution, and comprehensive analytical documentation.
What is the primary mechanism of the CJC-1295 and Ipamorelin research peptide blend?
The combination operates via dual-pathway activation of the somatotropic axis. CJC-1295 acts as a GHRH receptor agonist, while Ipamorelin selectively targets the ghrelin receptor (GHSR-1a). Preclinical studies show this dual action produces a synergistic release of growth hormone that exceeds the effect of either compound alone.
Does Ipamorelin elevate prolactin or cortisol levels in laboratory models?
No. In vitro pituitary assays and animal models demonstrate that Ipamorelin is highly selective for GHSR-1a, stimulating growth hormone release without producing significant spikes in adrenocorticotropic hormone (ACTH), cortisol, or prolactin.
How is the purity of PX1 Research peptides validated?
Every lot undergoes independent third-party analysis by an ISO 17025 accredited laboratory. Purity is determined by RP-HPLC (>99.0% standard), sequence identity is verified by mass spectrometry, and biological safety is confirmed via LAL endotoxin testing.
What diluent should be used to reconstitute CJC-1295 and Ipamorelin for in vitro assays?
Standard laboratory reconstitution is typically performed using Bacteriostatic Water or sterile, endotoxin-free PBS (pH 7.4). Selection depends on the specific cell line or analytical assay requirements.
What are the recommended storage temperatures for lyophilized peptides?
Lyophilized peptide vials should be stored at -20°C or -80°C for long-term stability. Avoid exposure to light, heat, and moisture. Reconstituted solutions should be maintained at 2°C to 8°C.
How does CJC-1295 without DAC differ from CJC-1295 with DAC?
CJC-1295 without DAC (also known as Modified GRF 1-29) lacks the Drug Affinity Complex moiety, resulting in a shorter half-life (approximately 30 minutes) that mimics physiological pulsatile GH release. CJC-1295 with DAC binds to serum albumin, extending its biological half-life to several days.
Where are PX1 Research peptides manufactured and shipped from?
All PX1 Research compounds are manufactured in USA-based, GMP-compliant facilities and shipped directly from fulfillment nodes in California and Arizona. Orders placed Monday through Friday ship same-day.
Are PX1 Research peptides suitable for human administration?
No. All products sold by PX1 Research are strictly for laboratory research use only (in vitro and preclinical animal research). They are not for human or veterinary use, medical therapy, or clinical ingestion.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.